



**BlueCross  
BlueShield**

Federal Employee Program.

## **TIKOSYN (dofetilide)**

### **RATIONALE FOR INCLUSION IN PA PROGRAM**

#### **Background**

Tikosyn (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Tikosyn blocks cardiac ion channels carrying the rapid component of the delayed rectifier potassium current  $I_{KR}$ . At clinically relevant concentrations, Tikosyn has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors (1).

#### **Regulatory Status**

FDA-approved indication: Tikosyn is indicated in patients with atrial fibrillation/atrial flutter (1).

#### **Summary**

Tikosyn (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Tikosyn blocks cardiac ion channels carrying the rapid component of the delayed rectifier potassium current  $I_{KR}$ . At clinically relevant concentrations, Tikosyn has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors (1).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of Tikosyn while maintaining optimal therapeutic outcomes.

#### **References**

1. Tikosyn [package insert]. New York, NY: Pfizer Inc.; July 2021.